MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
6 of the best: the billion-dollar biotechs putting China on the map
The ferocity of China's biopharmaceutical investment boom this year - fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump - may have surprised casual observers. But according to Helen Chen, one of the most respected analysts and advisers in China's ...
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
1 Monster Stock in the Making to Buy and Hold
The company's prospects improve with every clinical win.
Summit Therapeutics: A Risky Bet in the Biotech Arena?
Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet?
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
Company News for Oct 21, 2025
Companies in The News Are: SMMT, CLF, LHX, COO ...
What's Going On With Summit Therapeutics Stock On Monday? - Summit Therapeutics ( NASDAQ:SMMT )
Summit Therapeutics Inc. ( NASDAQ:SMMT ) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results. On Sunday, Summit Therapeutics shared results from the Phase 3 HARMONi-6 trial, conducted in China by its partner, Akeso Inc.
Top Stocks With Earnings This Week: Tesla, Netflix, RTX and More - Tesla ( NASDAQ:TSLA )
Retail investors are preparing for the first busy week in the third-quarter earnings season, with major defense contractors and other top stocks reporting. Here's a look at some retail favorites that individual investors will be watching. TSLA stock is moving. See the real-time price action here.
China's Akeso gets share boost as data shows cancer drug's benefits
Shares of Chinese drug firm Akeso - likened by some Western media outlets to artificial intelligence start-up DeepSeek - rose after the company unveiled clinical-trial data showing that its lung-cancer drug outperformed a highly effective existing treatment.
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF ( GSEW ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
1 Monster Stock in the Making to Buy and Hold
This biotech company was relatively unknown a few years ago.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Nvidia Meets Palantir, Rocket Lab On The '10-Bagger' Legends List - NVIDIA ( NASDAQ:NVDA )
Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly recovering market environment. NVDA stock is up 36% this year. See the real-time chart here
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Biohaven ( NYSE:BHVN ) , Avient ( NYSE:AVNT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Opendoor? No Meme Stocks, Ring The Register: Jim Cramer - Lumentum Holdings ( NASDAQ:LITE ) , Hubbell ( NYSE:HUBB )
"We're going to have to move on," Cramer on Summit Therapeutics. See the trading strategy with a perfect track record in 2025 [currently 34-0] → On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ringing the register on Opendoor Technologies Inc. OPEN. "We don't want to be in a meme ...
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - Summit Therapeutics ( NASDAQ:SMMT )
LOS ANGELES, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release.
Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion. - Summit Therapeutics ( NASDAQ:SMMT )
Investors can contact the law firm at no cost to learn more about recovering their losses
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Top 3 Health Care Stocks You'll Regret Missing In Q3 - CERo Therapeutics Hldgs ( NASDAQ:CERO ) , Lunai Bioworks ( NASDAQ:RENB )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.
Gold Moves Higher; Robinhood Shares Jump - Robinhood Markets ( NASDAQ:HOOD ) , Banco Macro ( NYSE:BMA )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 45,404.20 while the NASDAQ rose 0.67% to 21,845.34. The S&P 500 also rose, gaining, 0.25% to 6,497.56. Information technology shares jumped by 1.1% on ...
Why Is Summit Therapeutics Stock Sinking Monday? - Summit Therapeutics ( NASDAQ:SMMT )
Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese patients. Get the strategy to turn September's volatility into 10x trades → Summit Therapeutics Inc.
Why Is Summit Therapeutics Stock Sinking Monday? - Summit Therapeutics ( NASDAQ:SMMT )
Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese patients. Get the strategy to turn September's volatility into 10x trades → Summit Therapeutics Inc.
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - CNFinance Hldgs ( NYSE:CNF ) , Empresa Distribuidora y ( NYSE:EDN )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of New Fortress Energy Inc. NFE fell sharply in pre-market trading following second-quarter results.
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - CDT Equity ( NASDAQ:CDT ) , Acrivon Therapeutics ( NASDAQ:ACRV )
Shares of Robinhood Markets, Inc. HOOD rose sharply in pre-market trading. S&P Dow Jones Indices announced a sweeping update to its benchmarks late Friday, unveiling new additions to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600. Robinhood will replace Caesars Entertainment Inc.
3 No-Brainer Stocks to Buy Right Now
Investing in these pharmaceutical stocks is an easy decision.
Summit, Akeso Lung Cancer Drug Rivals Merck's Keytruda - Summit Therapeutics ( NASDAQ:SMMT )
Ivonescimab meets the overall survival endpoint in EGFR-mutant NSCLC, showing a strong survival benefit. HC Wainwright raises Summit's price target to $50, citing 85% approval odds. Tonight: Get a FREE TRADE, built by the seasonal trading strategy that's beating the S&P 500 by 6X this year.
JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Baidu ( NASDAQ:BIDU )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of The J. M. Smucker Company SJM fell sharply in pre-market trading after the company reported weaker-than-expected second-quarter results.
This Is What Whales Are Betting On Summit Therapeutics - Summit Therapeutics ( NASDAQ:SMMT )
Whales with a lot of money to spend have taken a noticeably bearish stance on Summit Therapeutics. Looking at options history for Summit Therapeutics SMMT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with ...
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN )
BeOne to sell Imdelltra royalties for $885 million upfront, plus $65 million option within a year. Royalty deal excludes China, with profit-sharing on sales above $1.5 billion annually. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → BeOne Medicines ...
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics ( NASDAQ: SMMT ) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.As is often the case ...
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.Three Motley Fool contributors think they've identified monster stocks in the making.
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday - BitMine Immersion Techs ( AMEX:BMNR ) , Brighthouse Finl ( NASDAQ:BHF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of Johnson & Johnson JNJ rose sharply during Wednesday's session after the company raised its FY2025 earnings guidance.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
